Oldaeus G, Kubista J, Ståhl E
Department of Pediatrics, Central Hospital, Jönköping, Sweden.
Ann Allergy Asthma Immunol. 1995 Jan;74(1):34-7.
Pulmonary administration of beta 2-agonists by means of pressurized metered dose inhaler is widely used in the treatment of asthma. Young children have difficulties in using these inhalers unless a spacer device is used. To overcome this problem inspiratory flow driven dry powder inhalers have been developed.
The aim of this study was to compare the efficacy and safety of the two powder inhalers Bricanyl Turbuhaler (terbutaline sulphate 0.5 mg t.i.d.) and Ventolin Rotahaler (salbutamol 0.4 mg t.i.d.) in 20 children 2 to 6 years old with mild to moderate asthma.
The study had an open randomized crossover design with 1 week run-in without treatment and the two treatment periods of 2 weeks each. Efficacy was measured with peak expiratory flow determination, asthma symptom scores, and need for rescue medication. Adverse events were recorded.
Peak expiratory flow increased significantly (P < .001) after both treatments. There were no statistically significant differences in peak expiratory flow, asthma symptom scores, need for extra inhalations, or adverse events between the devices. Most children (parents) preferred the Turbuhaler.
Both Bricanyl Turbuhaler and Ventolin Rotahaler seem to be effective and well tolerated in the treatment of asthma in preschool children. Of special interest is that even the youngest children in the study group were able to use these powder inhalers.
通过压力定量吸入器进行β2激动剂的肺部给药广泛应用于哮喘治疗。除非使用储雾罐装置,幼儿在使用这些吸入器时存在困难。为克服这一问题,已开发出吸气流量驱动的干粉吸入器。
本研究旨在比较两种干粉吸入器——布地奈德都保(硫酸特布他林0.5毫克,每日三次)和万托林准纳器(沙丁胺醇0.4毫克,每日三次)对20名2至6岁轻至中度哮喘儿童的疗效和安全性。
本研究采用开放随机交叉设计,有1周的无治疗导入期,以及两个各为期2周的治疗期。通过测定呼气峰值流速、哮喘症状评分和急救药物需求来衡量疗效。记录不良事件。
两种治疗后呼气峰值流速均显著增加(P <.001)。两种装置在呼气峰值流速、哮喘症状评分、额外吸入需求或不良事件方面无统计学显著差异。大多数儿童(家长)更喜欢都保。
布地奈德都保和万托林准纳器在治疗学龄前儿童哮喘方面似乎都有效且耐受性良好。特别值得注意的是,研究组中最小的儿童也能够使用这些干粉吸入器。